Breaking News, Trials & Filings

Novavax Submits Regulatory Filing for COVID Vax in United Arab Emirates

NVX-CoV2373 is a recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novavax, Inc., a biotechnology company dedicated to next-generation vaccines for serious infectious diseases, has submitted a regulatory filing to the Ministry of Health and Prevention (MoHaP) for emergency use of its COVID-19 vaccine in the United Arab Emirates (UAE).   NVX-CoV2373 is the company’s recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant. The filing includes clinical data from two pivotal Phase 3 trials: PREVENT-19, which included 30,000 participan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters